^
BIOMARKER:

EGFR mutation

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: B - Late Trials
Ann Oncol - 1 week
EGFR mutation
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
erlotinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
dacomitinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
atezolizumab
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
nivolumab + ipilimumab
Sensitive: A2 - Guideline
EGFR mutation
NSCLC
osimertinib
Sensitive: A2 - Guideline
EGFR mutation
NSCLC
EGFR inhibitor
Sensitive: A2 - Guideline
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
gefitinib
Sensitive: A2 - Guideline
EGFR mutation
NSCLC
bevacizumab + erlotinib
Sensitive: A2 - Guideline
EGFR mutation
NSCLC
bevacizumab
Sensitive: A2 - Guideline
EGFR mutation
NSCLC
erlotinib + ramucirumab
Sensitive: A2 - Guideline
EGFR mutation
NSCLC
icotinib
Sensitive: A2 - Guideline
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
erlotinib
Sensitive: A2 - Guideline
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
afatinib
Sensitive: A2 - Guideline
EGFR mutation
LUAD
gefitinib
Sensitive: B - Late Trials
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive: B - Late Trials
EGFR mutation
NSCLC
Tyrosine kinase inhibitor
Sensitive: B - Late Trials
EGFR mutation
Lung Cancer
Tyrosine kinase inhibitor
Sensitive: B - Late Trials
EGFR mutation
LUAD
afatinib
Sensitive: B - Late Trials
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: B - Late Trials
EGFR mutation
Lung Non-Small Cell Squamous Cancer
bevacizumab
Sensitive: B - Late Trials
EGFR mutation
NSCLC
gefitinib + rivoceranib
Sensitive: B - Late Trials
EGFR mutation
Solid Tumor
BDTX-189
Sensitive: B - Late Trials
EGFR mutation
NSCLC
nivolumab
Resistant: B - Late Trials
EGFR mutation
NSCLC
rociletinib
Sensitive: B - Late Trials
EGFR mutation
NSCLC
ABCP
Sensitive: B - Late Trials
EGFR mutation
LUAD
bevacizumab + erlotinib
Sensitive: C1 - Off-label
EGFR mutation
GBM
erlotinib
Sensitive: C1 - Off-label
EGFR mutation
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive: C1 - Off-label
EGFR mutation
LUAD
erlotinib
Sensitive: C1 - Off-label
EGFR mutation
Gastric Cancer
afatinib
Sensitive: C1 - Off-label
EGFR mutation
Lung Cancer
gefitinib
Sensitive: C1 - Off-label
EGFR mutation
NSCLC
pemetrexed
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
osimertinib + U3-1402
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
ASP8273
Sensitive: C2 – Inclusion Criteria
EGFR mutation
Lung Cancer
osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
Lung Cancer
bevacizumab + osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
sintilimab
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
tislelizumab
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
durvalumab
Sensitive: C2 – Inclusion Criteria
EGFR mutation
LUAD
bevacizumab
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
HM 78136B
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
U3-1402
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
osimertinib + savolitinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
ramucirumab
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
anlotinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
AB122 + AB928
Sensitive: C2 – Inclusion Criteria
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
erlotinib + ABBV-399
Sensitive: C2 – Inclusion Criteria
EGFR mutation
GBM
verteporfin
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
BBP-398
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
anlotinib + icotinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
AUY922
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
lazertinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
ipilimumab
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
osimertinib + selumetinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
osimertinib + ramucirumab
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
EGF816
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
bevacizumab + osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
rivoceranib + camrelizumab
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
durvalumab + MEDI9447
Sensitive: C2 – Inclusion Criteria
EGFR mutation
LUAD
osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
albumin-bound paclitaxel
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
nintedanib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
afatinib + osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
osimertinib + anlotinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
EGFR inhibitor + anlotinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
amivantamab-vmjw + lazertinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
NSCLC
toripalimab
Sensitive: C2 – Inclusion Criteria
EGFR mutation
LUAD
cetuximab + afatinib
Sensitive: C3 – Early Trials
EGFR mutation
LUAD
bevacizumab + afatinib
Sensitive: C3 – Early Trials
EGFR mutation
LUAD
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EGFR mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
EGFR mutation
NSCLC
osimertinib + rivoceranib
Sensitive: C3 – Early Trials
EGFR mutation
NSCLC
EGFR inhibitor + Angiogenesis inhibitor
Sensitive: C3 – Early Trials
EGFR mutation
NSCLC
PD-L1 inhibitor
Resistant: C3 – Early Trials
EGFR mutation
SCCHN
cetuximab + ISU104
Sensitive: C3 – Early Trials
EGFR mutation
Lung Non-Small Cell Squamous Cancer
erlotinib + ABBV-399
Sensitive: C3 – Early Trials
EGFR mutation
NSCLC
gefitinib + savolitinib
Sensitive: C3 – Early Trials
EGFR mutation
NSCLC
olaparib + gefitinib
Resistant: C3 – Early Trials
EGFR mutation
NSCLC
cetuximab + afatinib
Resistant: C3 – Early Trials
EGFR mutation
NSCLC
ALK inhibitor
Sensitive: C3 – Early Trials
EGFR mutation
NSCLC
X-396
Resistant: C3 – Early Trials
EGFR mutation
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
EGFR mutation
Solid Tumor
ABSK-091
Sensitive: C3 – Early Trials
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + afatinib
Sensitive: C3 – Early Trials
EGFR mutation
NSCLC
cisplatin + albumin-bound paclitaxel
Sensitive: C3 – Early Trials
EGFR mutation
NSCLC
erlotinib + anlotinib
Sensitive: C3 – Early Trials